Kurkumin’in Osteosarkomada Doğal RANKL İnhibitörü Olarak Biyolojik Değerlendirilmesi

Osteosarkoma çocuklar ve ergenlik çağındaki kişilerde önemli bir sağlık sorunudur. Metastaz osteosarkoma hastalarının yaklaşık yüzde yirmisinde gözlenmektedir. RANK/RANKL/OPG sinyal yolağı osteosarkoma ve metastazında görev almaktadır. Özellikle RANKL’nin aşırı ekspresyonu osteoklast ve osteosarkoma oluşumu ile ilişkilidir. Bundan dolayı RANKL’nin aktivitesinin inhibisyonu osteosarkoma tedavisinde önemli bir metottur. Bu çalışmada kurkumin osteosarkoma hücrelerinde RANKL inhibitörü olarak değerlendirilmiştir. Bu bağlamda kurkumin’in anti-proliferatif ve anti-invaziv özellikleri Saos-2 hücre hattında in-vitro ve hesapsal teknikler ile belirlenmiştir. Elde edilen sonuçlar kurkumin’in osteosarkoma ve metastazında potansiyeli olabileceğini göstermiştir.

Anahtar Kelimeler:

Osteosarkoma, Kurkumin, RANKL, Saos-2

Biological Evaluation of Curcumin As a Natural RANKL Inhibitor in Osteosarcoma

Osteosarcoma is an important health problem among children and teenagers. Metastases is observed in about twenty percent of osteosarcoma patients. RANK/RANKL/OPG signaling pathway is involved in formation of osteosarcoma and its metastases. Especially, the overexpression of RANKL is related to osteoclast and osteosarcoma formation. Therefore, inhibition of RANKL activity has been significant treatment method of osteosarcoma. In this study, curcumin was evaluated as RANKL inhibitor in osteosarcoma cells. In this context, anti-proliferative and anti-invasive properties of the curcumin were determined with in-vitro and computational assays in Saos-2 cell line. Obtained results showed that curcumin may has a potential for treatment of osteosarcoma and its metastases.

Keywords:

Osteosarcoma, Curcumin, RANKL, Saos-2,

PDF

___

[1] Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther. 2007; 7(2): 169-81.
[2] Kim HJ, Chalmers PN, Morris CD. Pediatric osteogenic sarcoma. Curr Opin Pediatr. 2010; 22(1): 61-6.
[3] Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009; 152: 3-13.
[4] Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473(2): 139-46.
[5] Baud'huin M, Duplomb L, Ruiz Velasco C, Fortun Y, Heymann D, Padrines M. Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev Anticancer Ther. 2007; 7(2): 221-32.
[6] Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020; 40:2.
[7] Ando K, Mori K, Rédini F, Heymann D. RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol. 2008; 5(3): 263-8.
[8] Salehi B, Stojanović-Radić Z, Matejić J, Sharifi-Rad M, Anil Kumar NV, Martins N, et al. The therapeutic potential of curcumin: A review of clinical trials. Eur J Med Chem. 2019; 163: 527-45.
[9] Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009; 41(1): 40-59.
[10] Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol. 2008; 75(4): 787-809.
[11] Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23(1A): 363-98.
[12] Gümüs M, Ozgur A, Tutar L, Disli A, Koca İ, Tutar Y. Design, Synthesis, and Evaluation of Heat Shock Protein 90 Inhibitors in Human Breast Cancer and Its Metastasis. Curr Pharm Biotechnol. 2016; 17(14): 1231-45.
[13] Koca İ, Gümüş M, Özgür A, Dişli A, Tutar Y. A Novel Approach to Inhibit Heat Shock Response as Anticancer Strategy by Coumarine Compounds Containing Thiazole Skeleton. Anticancer Agents Med Chem. 2015; 15(7): 916-30.
[14] Koca İ, Özgür A, Er M, Gümüş M, Açıkalın Coşkun K, Tutar Y. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis. Eur J Med Chem. 2016; 122: 280-90.
[15] Kruger NJ. The Bradford method for protein quantitation. Methods Mol Biol. 1994; 32: 9-15.
[16] Cramer J, Sager CP, Ernst B. Hydroxyl groups in synthetic and natural-product-derived therapeutics: A perspective on a common functional group. J Med Chem. 2019; 62: 8915-8930.